BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 30803299)

  • 1. HIV Infection-Associated Frailty: The Solution for Now Is Antiretroviral Drugs: A Perspective.
    Klotz SA; Bradley N; Smith S; Ahmad N
    J Int Assoc Provid AIDS Care; 2019; 18():2325958219831045. PubMed ID: 30803299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dynamic association between Frailty, CD4 and CD4/CD8 ratio in people aging with HIV.
    Guaraldi G; Zona S; Silva AR; Menozzi M; Dolci G; Milic J; Carli F; Mussini C
    PLoS One; 2019; 14(2):e0212283. PubMed ID: 30763363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of lifelong cumulative HIV viremia on long-term recovery of CD4+ cell count and CD4+/CD8+ ratio among patients on combination antiretroviral therapy.
    Seng R; Goujard C; Krastinova E; Miailhes P; Orr S; Molina JM; Saada M; Piroth L; Rouzioux C; Meyer L;
    AIDS; 2015 Mar; 29(5):595-607. PubMed ID: 25715104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
    Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
    AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-Treatment Controllers: Role in HIV "Cure" Research.
    Cockerham LR; Hatano H; Deeks SG
    Curr HIV/AIDS Rep; 2016 Feb; 13(1):1-9. PubMed ID: 26781112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of hepatitis C virus coinfection on T-cell dynamics in long-term HIV-suppressors under combined antiretroviral therapy.
    Zaegel-Faucher O; Bregigeon S; Cano CE; Obry-Roguet V; Nicolino-Brunet C; Tamalet C; Dignat-George F; Poizot-Martin I
    AIDS; 2015 Jul; 29(12):1505-10. PubMed ID: 26244390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication.
    Alatrakchi N; Duvivier C; Costagliola D; Samri A; Marcelin AG; Kamkamidze G; Astriti M; Agher R; Calvez V; Autran B; Katlama C
    AIDS; 2005 Jan; 19(1):25-33. PubMed ID: 15627030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of antiretroviral therapies in mucocutaneous manifestations in HIV-infected children over a period of two decades.
    Seoane Reula E; Bellon JM; Gurbindo D; Muñoz-Fernandez MA
    Br J Dermatol; 2005 Aug; 153(2):382-9. PubMed ID: 16086754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The independent effect of drug resistance on T cell activation in HIV infection.
    Hunt PW; Deeks SG; Bangsberg DR; Moss A; Sinclair E; Liegler T; Bates M; Tsao G; Lampiris H; Hoh R; Martin JN
    AIDS; 2006 Mar; 20(5):691-9. PubMed ID: 16514299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection.
    Eggena MP; Barugahare B; Okello M; Mutyala S; Jones N; Ma Y; Kityo C; Mugyenyi P; Cao H
    J Infect Dis; 2005 Mar; 191(5):694-701. PubMed ID: 15688282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline CD4/CD8 T-Cell Ratio Predicts Prompt Immune Restoration Upon cART Initiation.
    Bellissimo F; Pinzone MR; Celesia BM; Cacopardo B; Nunnari G
    Curr HIV Res; 2016; 14(6):491-496. PubMed ID: 27074946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case for reduced frequency of CD4 count monitoring for children on combination antiretroviral therapy with consistently undetectable HIV viral load.
    Johnson SM; Standing JF; Klein N; Irwin AD; Shingadia D; Lonsdale DO; Gilmour KC; Flynn J; Manns C; Clapson M; Bamford A
    HIV Med; 2019 Apr; 20(4):e8-e9. PubMed ID: 30693658
    [No Abstract]   [Full Text] [Related]  

  • 13. Impaired CD4+ T-cell restoration in the small versus large intestine of HIV-1-positive South Africans receiving combination antiretroviral therapy.
    Cassol E; Malfeld S; Mahasha P; Bond R; Slavik T; Seebregts C; Poli G; Cassol S; van der Merwe SW; Rossouw T
    J Infect Dis; 2013 Oct; 208(7):1113-22. PubMed ID: 23749968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma.
    Powles T; Imami N; Nelson M; Gazzard BG; Bower M
    AIDS; 2002 Mar; 16(4):531-6. PubMed ID: 11872995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy.
    Chang JJ; Wightman F; Bartholomeusz A; Ayres A; Kent SJ; Sasadeusz J; Lewin SR
    J Virol; 2005 Mar; 79(5):3038-51. PubMed ID: 15709024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond antiretroviral therapy: early interventions to control HIV-1 infection.
    Gunst JD; Tolstrup M; Søgaard OS
    AIDS; 2017 Jul; 31(12):1665-1667. PubMed ID: 28463884
    [No Abstract]   [Full Text] [Related]  

  • 17. Changes in levels of T cell subpopulations to monitor the response to antiretroviral therapy among HIV-1-infected patients during two years of HIV-1 replication suppression.
    Zhang JC; Zhang HJ; Li Y; Jing D; Liu Q; Zhao K; Liu QQ; Zhuang Y; Kang WZ; Sun YT
    Scand J Infect Dis; 2013 May; 45(5):368-77. PubMed ID: 23186319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-level human herpesvirus-8 viremia and multicentric Castleman's disease following initiation of highly active antiretroviral therapy.
    Lumley S; Madge S; Nugent D; Ainsworth J; Dervisevic S; Schmitt C; Schulz TF; Johnson MA; Cwynarski K; Webster DP
    AIDS; 2014 Jul; 28(11):1698-700. PubMed ID: 25197975
    [No Abstract]   [Full Text] [Related]  

  • 19. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
    Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated with favourable outcome.
    Onen NF; Overton ET; Presti R; Blair C; Powderly WG; Mondy K
    HIV Med; 2009 Aug; 10(7):439-46. PubMed ID: 19459993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.